Study of electrochemical behavior of escitalopram oxalate using hanging mercury drop electrode and its determination in human urine and pharmaceuticals

Badulla W. F., ÖZCAN S., ATKOŞAR Z., ARLİ G.

JOURNAL OF THE IRANIAN CHEMICAL SOCIETY, vol.18, no.4, pp.739-750, 2021 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 18 Issue: 4
  • Publication Date: 2021
  • Doi Number: 10.1007/s13738-020-02066-y
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier
  • Page Numbers: pp.739-750
  • Keywords: Escitalopram oxalate, Cyclic voltammetry, Differential pulse voltammetry, Hanging mercury dropping electrode, Urine samples, LIQUID-CHROMATOGRAPHY, MASS-SPECTROMETRY, HUMAN PLASMA, POLAROGRAPHY, VOLTAMMETRY, ADSORPTION, EXTRACTION, DRUGS
  • Anadolu University Affiliated: Yes


Escitalopram oxalate (ESC-OX) is among the most currently used antidepressant drugs. This study aimed to determine ESC-OX in human urine and different pharmaceutical dosage forms via the electrochemical method. The electrochemical behavior of ESC-OX was investigated using cyclic voltammetry (CV) and differential pulse voltammetry (DPV) techniques at hanging mercury dropping electrode (HMDE). The maximum reduction potential was determined to be - 0.55 and - 0.57 V at pH 6.5 in a cell containing 5% (v/v) methanol and 0.3 M KCl. Under the optimized conditions, the calibration curve of the cathodic peak current versus the concentration was linear in the range of 4.143-29.0 mu g mL(-1). The LOD and LOQ were found to be 1.15 mu g mL(-1)and 1.31 mu g mL(-1), 3.490 mu g mL(-1)and 3.97 mu g mL(-1)for pharmaceutical and urine samples, respectively. The investigation of electrochemical reduction of ESC-OX on the HDME by using CV resulted in a quasi-reversibility, mainly diffusion-controlled reaction that involves a four-electron reduction of the nitrile group. For analytical purposes, a stable and well-defined peak was obtained in DPV mode. The average accuracy was found to be 101.60% +/- 0.48 and 99.72% +/- 5.64 for pharmaceutical and urine samples, respectively. Moreover, the developed method was precise with RSD % below 2% for both samples. The validation of the developed method was carried out as stated in the ICH Q2(R) 1 guideline. The proposed technique was effectively utilized for the determination of ESC-OX in different pharmaceutical formulations and urine samples. Neither excipients nor endogenous substances have electroactive interferences.